A New Alzheimer's Drug May Be the Most Effective One YetDonanemab (Kisunla) approved by FDA for Alzheimer's is shown to be highly effective, slowing cognitive decline and improving daily function.
FDA approves new Alzheimer's treatment, donanemab from Eli LillyThe FDA approved a new Alzheimer's treatment, donanemab, by Eli Lilly, aiming to slow brain decline in early-stage patients.
FDA advisors strongly back new Alzheimer's drug, despite risks and limitationsFDA advisors recommend approval of Alzheimer's drug donanemab for slowing disease progression.
Alzheimer's drug with modest benefits wins backing of FDA advisersDonanemab slows cognitive decline in early Alzheimer's stages but lacks symptom reversal, raising concerns about its lasting effects.
Alzheimer's Drug with Modest Benefits Gets Green Light from FDA AdvisersDonanemab, a drug for Alzheimer's, gains unanimous approval for treating cognitive decline in early-stage patients but has limited effects and usage restrictions.
New Drug Approved for Early Alzheimer'sThe FDA approved a new drug for Alzheimer's disease, Donanemab (Kisunla), shown to slow cognitive decline in early stages with significant safety risks.
A New Alzheimer's Drug May Be the Most Effective One YetDonanemab (Kisunla) approved by FDA for Alzheimer's is shown to be highly effective, slowing cognitive decline and improving daily function.
FDA approves new Alzheimer's treatment, donanemab from Eli LillyThe FDA approved a new Alzheimer's treatment, donanemab, by Eli Lilly, aiming to slow brain decline in early-stage patients.
FDA advisors strongly back new Alzheimer's drug, despite risks and limitationsFDA advisors recommend approval of Alzheimer's drug donanemab for slowing disease progression.
Alzheimer's drug with modest benefits wins backing of FDA advisersDonanemab slows cognitive decline in early Alzheimer's stages but lacks symptom reversal, raising concerns about its lasting effects.
Alzheimer's Drug with Modest Benefits Gets Green Light from FDA AdvisersDonanemab, a drug for Alzheimer's, gains unanimous approval for treating cognitive decline in early-stage patients but has limited effects and usage restrictions.
New Drug Approved for Early Alzheimer'sThe FDA approved a new drug for Alzheimer's disease, Donanemab (Kisunla), shown to slow cognitive decline in early stages with significant safety risks.
The Next Potential Alzheimer's Drug Clears a Big HurdleDrug companies are making progress in Alzheimer's treatment with FDA panel's positive evaluation of Eli Lilly's donanemab.
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer's DrugFDA advisors support Alzheimer's drug Donanemab despite risks.